Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients

American Journal of Psychiatry

Volumn 161, Issue 10, 2004, Pages 1822-1828

  Adler, Lawrence E ^a   Olincy, Ann ^a   Cawthra, Ellen M ^a   McRae, Kara A ^a   Harris, Josette G ^a   Nagamoto, Herbert T ^a   Waldo, Merilyne C ^a,b   Hall, Mei Hua ^a   Bowles, Amanda ^a   Woodward, Laurie ^a   Ross, Randal G ^a   Freedman, Robert ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; AUDITORY STIMULATION; CONDITIONING; CONTROLLED STUDY; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CELL INHIBITION; PRIORITY JOURNAL; RELATIVE; SCHIZOPHRENIA; SENSORY DYSFUNCTION;

EID: 4744338411     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.161.10.1822     Document Type: Article

References (48)

1. McGhie A, Chapman JS: Disorders of attention and perception in early schizophrenia. Br J Med Psychol 1961; 34:103-116
2. Braff DL, Saccuzzo DP: Interhemispheric visual masking. Percept Mot Skills 1985; 60:495-502
3. Braff DL, Grillon C, Geyer MA: Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992; 49:206-215
4. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R: Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 1982; 17:639-654
5. Adler LE, Waldo MC, Freedman R: Neurophysiologic studies of sensory gating in schizophrenia: comparison of auditory and visual responses. Biol Psychiatry 1985; 20:1284-1296
6. Adler LE, Gerhardt GA, Franks R, Baker N, Nagamoto HT, Drebing C, Freedman R: Sensory physiology and catecholamines in schizophrenia and mania. Psychiatry Res 1990; 31: 297-309
7. Adler LE, Waldo MC, Tatcher A, Cawthra E, Baker N, Freedman R: Lack of relationship of auditory gating defects to negative symptoms in schizophrenia. Schizophr Res 1990; 3:131-138
8. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD: Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 1983; 18:537-551
9. Boutros NN, Zouridakis G, Overall J: Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 1991; 22:40-55
10. Erwin RJ, Mawhinney-Hee M, Gur RC, Gur RE: Midlatency auditory evoked responses in schizophrenia. Biol Psychiatry 1991; 30:430-442
11. Judd LL, McAdams L, Budnick B, Braff DL: Sensory gating deficits in schizophrenia: new results. Am J Psychiatry 1992; 149: 488-493
12. Clementz BA, Geyer MA, Braff DL: P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiatry 1997; 41:1035-1044
13. Cadenhead KS, Geyer MA, Butler RW, Perry W, Sprock J, Braff DL: Information processing deficits of schizophrenia patients: relationship to clinical ratings, gender and medication status. Schizophr Res 1997; 28:51-62
14. Bolino F, Di Michele V, Di Cicco L, Manna V, Daneluzzo E, Casacchia M: Sensorimotor gating and habituation evoked by electro-cutaneous stimulation in schizophrenia. Biol Psychiatry 1994; 36:670-679
15. Eccles JC: The Inhibitory Pathways of the Central Nervous System. Liverpool, UK, University Press, 1969
16. Waldo MC, Carey G, Myles-Worsley M, Cawthra E, Adler LE, Nagamoto HT, Wender P, Byerley W, Plaetke R, Freedman R: Co-distribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res 1991; 39:257-268
17. Siegel C, Waldo M, Mizner G, Adler LE, Freedman R: Deficits in sensory gating in schizophrenic patients and their relatives: evidence obtained with auditory evoked responses. Arch Gen Psychiatry 1984; 41:607-612
18. Clementz BA, Geyer MA, Braff DL: Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry 1998; 155:1691-1694
19. Cullum CM, Harris JG, Waldo MC, Smernoff E, Madison A, Nagamoto HT, Griffith J, Adler LE, Freedman R: Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res 1993; 10:131-141
20. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD: Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 1983; 18:537-551
21. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae K, Freedman R: Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry 1996; 40:181-188
22. Nagamoto HT, Adler LE, McRae KA, Huettl P, Cawthra E, Gerhardt G, Hea R, Griffith J: Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement. Biol Psychiatry 1999; 39:10-17
23. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertaining and scaling. Psychopharmacol Bull 1988; 24:97-99
24. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL: Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 2000; 157:767-771
25. Yee CM, Nuechterlein KH, Morris SE, White PM: P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol 1998; 107:691-698
26. Arango C, Summerfelt A, Buchanan RW: Olanzapine effects on auditory sensory gating in schizophrenia. Am J Psychiatry 2003; 160:2066-2068
27. Kinon BJ, Lieberman JA: Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996; 124:2-34
28. Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S: Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999; 249(suppl 4):83-89
29. Ichikawa J, Meltzer HY: Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 1999; 249(suppl 4):90-98
30. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R: Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002; 59:1085-1096
31. Nagamoto HT, Adler LE, Waldo MC, Freedman R: Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol Psychiatry 1989; 25:549-561
32. Coppola R: Isolating low frequency activity in EEG spectrum analysis. Electroencephalogr Clin Neurophysiol 1979; 46:224-226
33. Arnfred SM, Chen ACN, Glenthøj BY, Hemmingsen RP: Normal P50 gating in unmedicated schizophrenia outpatients. Am J Psychiatry 2003; 160:2236-2238
34. Kanno A, Nakasata N, Murayama N, Yoshimoto T: Middle and long latency peak sources in auditory evoked magnetic fields for tone bursts in humans. Neurosci Lett 2000; 293:187-190
35. Yvert B, Crouzeix A, Bertrand O, Seither-Preisler A, Pantev C: Multiple supratemporal sources of magnetic and electric auditory evoked middle latency components in humans. Cereb Cortex 2001; 11:411-423
36. Clementz BA, Barber SK, Dzau JR: Knowledge of stimulus repetition affects the magnitude and spatial distribution of low-frequency event-related brain potentials. Audiol Neurootol 2002; 7:303-314
37. Nagamoto HT, Adler LE, Waldo MC, Griffith J, Freedman R: Gating of auditory response in schizophrenics and normal controls: effects of recording site and stimulation interval on the P50 wave. Schizophr Res 1991; 4:31-40
38. Erwin RJ, Mawhinney-Hee M, Gur RC, Gur RE: Midlatency auditory evoked responses in schizophrenia. Biol Psychiatry 1991; 30:430-442
39. Meltzer HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989; 99:S18-S27
40. Tuunainen A, Wahlbeck K, Gilbody SM: Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000966
41. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W: Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997; 94:587-592
42. Shirazi-Southall S, Rodriguez DE, Nomikos GG: Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 2002; 26:583-594
43. Adler LE, Hoffer LD, Griffith J, Waldo M, Freedman R: Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992; 32:607-616
44. Adler LE, Hoffer LD, Wiser A, Freedman R: Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993; 150:1856-1861
45. Simosky JK, Stevens KE, Kem WR, Freedman R: Intragastric DMXB-A, an α7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol Psychiatry 2001; 50:493-500
46. Combs DR, Advokat C: Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia. Schizophr Res 2000; 46:129-137
47. Ramirez MH, Cenarruzabeitia E, Lasheras B, Del Rio J: Involvement of GABA systems in acetylcholine release induced by 5HT3 receptor blockade in slices from rat entorninal cortex. Brain Res 1996; 712:274-280
48. Adler LE, Cawthra EC, McRae KA, Harris J, Nagamoto HT, Waldo MC, Olincey A: Ondansetron improves P50 auditory gating in medicated schizophrenic patients. Am J Psychiatry (in press)